Leap Therapeutics closes $58.9M private placement led by Winklevoss Capital to pursue digital asset treasury

CYPHERPUNK TECHNOLOGIES INC.

Gross proceeds of ~$58.88M from sale of 15.2M shares, 80.8M pre-funded warrants, and 72.0M common warrants.
Winklevoss Capital leads the deal; gets right to nominate two board members, one of whom will serve as chair.
Proceeds to fund a digital asset treasury strategy and continue development of FL-501 and sirexatamab.
Common warrants priced at $0.5335/share, 10-year term; pre-funded warrants exercisable at $0.001/share with no expiration.
Parcrest serves as placement agent; receives $1.5M fee ($1M cash plus warrants for 4M shares).

item 1.01item 3.02item 7.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.